Vaccine Info

COVID-19

Authored by
Staff
Last reviewed
November 29, 2022
Share

COVID-19 In 2022

During the COVID-19 pandemic, the U.S. FDA approved and Authorized various vaccines, antivirals, and monoclonal antibody therapies to prevent and treat people infected with the SARS-CoV-2 coronavirus that causes COVID-19.

COVID-19 Vaccines 

The U.S. Food and Drug Administration (FDA) Approved two COVID-19 vaccines and issued various Emergency Use Authorizations. The initial FDA Approval was for the Pfizer-BioNTech Comirnaty vaccine on August 23, 2021, followed by Moderna's SpikeVax vaccine on February 4, 2022.

And the FDA Authorized the Jcovden COVID-19 vaccine from Janssen - Johnson & Johnson on February 27, 2021, then on July 13, 2022, the FDA Authorized the Novavax COVID-19 Vaccine (Nuvaxovid™).

The U.S. CDC reported in November 2022 that about 68% of the U.S. population had been 'fully vaccinated' with an Approve/Authorized COVID-19 vaccine, and about 49% of eligible people have been 'boosted' with a third vaccination.

COVID-19 Vaccination News

In the U.S. CDC's Advisory Committee on Immunization Practices (ACIP) meeting on October 20, 2022, the members unanimously voted to expand the 2023 vaccination schedules. The ACIP reviewed the following presentations led by Dr. Grace Lee. On October 19, 2022, the CDC recommended using the Novavax COVID-19 Vaccine, Adjuvanted, as a booster for adults. And on September 13, 2022, the CDC's Clinician Outreach and Communication Activity Call reviewed: Recommendations for Bivalent COVID-19 Booster Doses in People Ages 12 Years and Older.

And from a main-street access perspective, the Journal of the American Pharmacists Association found that by August 2022, pharmacists had administered 270 million COVID-19 vaccinations, cared for about 5.4 million hospitalized COVID-19 patients, administered 42 million COVID tests, and provided over 100,000 monoclonal antibody treatments.

COVID-19 Antivirals

The U.S. FDA has Approved and Authorized various antivirals (oral and IV) to treat COVID-19 infections. 

COVID-19 Monoclonal Antibody

The U.S. FDA has Authorized various monoclonal antibody therapies during the COVID-19 pandemic.

Vaccine Adverse Event Reporting System

The Vaccine Adverse Event Reporting System is passive, meaning it relies on individuals to send in reports of their experiences. Anyone can submit a vaccine side effect report to VAERS, including parents and patients. Search vaccines.gov, text your zip code to 438829 or call 1-800-232-0233 to find COVID-19 vaccine, antivirals, or antibody locations, such as pharmacies.

Clinical Trials

No clinical trials found